APOBEC3 Deletion Polymorphism is Associated with Epithelial Ovarian Cancer Risk Among Chinese Women

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2014 Mar 1

PMID 24577894

Citations 18

Authors

Guannan Qi

Huijuan Xiong

Changju Zhou

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer remains the leading cause of death from gynecological malignancies and the second most common gynecological malignancy among women worldwide. However, the etiology still remains largely unknown. Previous studies identified APOBEC3 gene deletions were significantly associated with higher breast cancer risk in both European and Chinese women. Considering both breast and ovarian cancers being hormonally driven and sharing multiple risk factors, we performed this case-control study to evaluate the association between APOBEC3 deletion and epithelial ovarian cancer (EOC) risk. We analyzed the APOBEC3 deletion in a case-control study of 2,938 Chinese women (including 1,374 EOC cases and 1,564 healthy controls). All participants were genotyped using real-time qualitative PCR (qPCR). APOBEC3 deletion was significant associated with EOC risk, with ORs (95 % CIs) of 1.46 (1.14-1.86) associated with one copy deletion and 2.53 (0.91-7.06) associated with two copy deletion compared with subjects with no deletion (P for trend =1.50 × 10(-3)). Additional adjustments and stratified analyses did not change the results materially. Our data suggests that the loss genotypes of APOBEC3 deletion predispose their carriers to EOC.

Citing Articles

Development and validation of a novel prognostic lncRNA signature based on the APOBEC3 family genes in gastric cancer.

Qi J, Wu W, Chen J, Han X, Hao Z, Han Y Heliyon. 2024; 10(6):e28307.

PMID: 38560679 PMC: 10979227. DOI: 10.1016/j.heliyon.2024.e28307.

APOBEC Mutagenesis in Cancer Development and Susceptibility.

Dananberg A, Striepen J, Rozowsky J, Petljak M Cancers (Basel). 2024; 16(2).

PMID: 38254863 PMC: 10814203. DOI: 10.3390/cancers16020374.

Constructing an APOBEC-related gene signature with predictive value in the overall survival and therapeutic sensitivity in lung adenocarcinoma.

Luo Y, Wang H, Zhong J, Shi J, Zhang X, Yang Y Heliyon. 2023; 9(11):e21336.

PMID: 37954334 PMC: 10637964. DOI: 10.1016/j.heliyon.2023.e21336.

APOBEC3: Friend or Foe in Human Papillomavirus Infection and Oncogenesis?.

Warren C, Santiago M, Pyeon D Annu Rev Virol. 2022; 9(1):375-395.

PMID: 35671565 PMC: 9637027. DOI: 10.1146/annurev-virology-092920-030354.

Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer.

Gansmo L, Sofiyeva N, Bjornslett M, Romundstad P, Hveem K, Vatten L Sci Rep. 2021; 11(1):23463.

PMID: 34873230 PMC: 8648731. DOI: 10.1038/s41598-021-02820-z.

References

Eichler E, Flint J, Gibson G, Kong A, Leal S, Moore J . Missing heritability and strategies for finding the underlying causes of complex disease. Nat Rev Genet. 2010; 11(6):446-50. PMC: 2942068. DOI: 10.1038/nrg2809. View

Zhang T, Cai J, Chang J, Yu D, Wu C, Yan T . Evidence of associations of APOBEC3B gene deletion with susceptibility to persistent HBV infection and hepatocellular carcinoma. Hum Mol Genet. 2012; 22(6):1262-9. DOI: 10.1093/hmg/dds513. View

Wedekind J, Dance G, Sowden M, Smith H . Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends Genet. 2003; 19(4):207-16. DOI: 10.1016/S0168-9525(03)00054-4. View

Ma X, Beeghly-Fadiel A, Shu X, Li H, Yang G, Gao Y . Anthropometric measures and epithelial ovarian cancer risk among Chinese women: results from the Shanghai Women's Health Study. Br J Cancer. 2013; 109(3):751-5. PMC: 3738128. DOI: 10.1038/bjc.2013.384. View

Leonard B, Hart S, Burns M, Carpenter M, Temiz N, Rathore A . APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res. 2013; 73(24):7222-31. PMC: 3867573. DOI: 10.1158/0008-5472.CAN-13-1753. View

Kurman R, Shih I . The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010; 34(3):433-43. PMC: 2841791. DOI: 10.1097/PAS.0b013e3181cf3d79. View

Sankaranarayanan R, Ferlay J . Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2005; 20(2):207-25. DOI: 10.1016/j.bpobgyn.2005.10.007. View

Dorjgochoo T, Shu X, Li H, Qian H, Yang G, Cai H . Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006. Int J Cancer. 2009; 124(10):2442-9. PMC: 2666967. DOI: 10.1002/ijc.24232. View

Stenglein M, Burns M, Li M, Lengyel J, Harris R . APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat Struct Mol Biol. 2010; 17(2):222-9. PMC: 2921484. DOI: 10.1038/nsmb.1744. View

10.

Burns M, Lackey L, Carpenter M, Rathore A, Land A, Leonard B . APOBEC3B is an enzymatic source of mutation in breast cancer. Nature. 2013; 494(7437):366-70. PMC: 3907282. DOI: 10.1038/nature11881. View

11.

Xuan D, Li G, Cai Q, Deming-Halverson S, Shrubsole M, Shu X . APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry. Carcinogenesis. 2013; 34(10):2240-3. PMC: 3786378. DOI: 10.1093/carcin/bgt185. View

12.

Kuong K, Loeb L . APOBEC3B mutagenesis in cancer. Nat Genet. 2013; 45(9):964-5. PMC: 3965181. DOI: 10.1038/ng.2736. View

13.

Burns M, Temiz N, Harris R . Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet. 2013; 45(9):977-83. PMC: 3902892. DOI: 10.1038/ng.2701. View

14.

McLaughlin J, Risch H, Lubinski J, Moller P, Ghadirian P, Lynch H . Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol. 2007; 8(1):26-34. DOI: 10.1016/S1470-2045(06)70983-4. View

15.

Holschneider C, Berek J . Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000; 19(1):3-10. DOI: 10.1002/1098-2388(200007/08)19:1<3::aid-ssu2>3.0.co;2-s. View

16.

Holmes R, Malim M, Bishop K . APOBEC-mediated viral restriction: not simply editing?. Trends Biochem Sci. 2007; 32(3):118-28. DOI: 10.1016/j.tibs.2007.01.004. View

17.

Stankiewicz P, Lupski J . Structural variation in the human genome and its role in disease. Annu Rev Med. 2010; 61:437-55. DOI: 10.1146/annurev-med-100708-204735. View

18.

Zheng W, Danforth K, Tworoger S, Goodman M, Arslan A, Patel A . Circulating 25-hydroxyvitamin D and risk of epithelial ovarian cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010; 172(1):70-80. PMC: 2892541. DOI: 10.1093/aje/kwq118. View

19.

Long J, Delahanty R, Li G, Gao Y, Lu W, Cai Q . A common deletion in the APOBEC3 genes and breast cancer risk. J Natl Cancer Inst. 2013; 105(8):573-9. PMC: 3627644. DOI: 10.1093/jnci/djt018. View

20.

Chiu Y, Greene W . The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol. 2008; 26:317-53. DOI: 10.1146/annurev.immunol.26.021607.090350. View